Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer

Amsterdam, The Netherlands, 1 July 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that Dr C....

BioGeneration Ventures closes BGV IV fund at €105 million

Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq   Investment focus on entrepreneurial innovation in therapeutics in Europe Total assets under management >€220 million ($250m) Naarden, The...

Azafaros expands executive management team and operations

• Company attracts three experienced industry executives to lead preclinical and clinical development as well as finance and operations• Company incorporates Swiss subsidiary and gains additional investment from Schroder Adveq Leiden, The Netherlands, June 10th, 2020...

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

--New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates-- Ghent, Belgium – June 3, 2020 - Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the...